Ferric Carboxymaltose

Ferric Carboxymaltose (FCM) is a scientifically advanced intravenous iron replacement therapy developed for effective management of iron deficiency anemia. Unlike conventional iron salts, it is a carbohydrate-based iron (III) complex, offering superior stability, safety, and patient tolerability. The formulation is colourless, odourless, and non-hygroscopic, eliminating the metallic taste and moisture sensitivity commonly associated with traditional iron preparations. As a leading API manufacturer, WBCIL follows strict cGMP and ISO quality systems, backed by manufacturing expertise since 1962, ensuring consistent potency, purity, and safety. Key Therapeutic Advantages: • High-dose iron delivery with rapid correction of iron deficiency • Controlled iron release minimizing adverse reactions • Fewer infusions compared to conventional IV iron therapies • Improved patient compliance and clinical outcomes WBCIL Product Highlights: • Two patents held by WBCIL on Ferric Carboxymaltose • Two eminent scientific journals have published studies on WBCIL’s FCM • Minimal hypersensitivity reactions reported • Sameness study completed with the innovator product • Compliant with Indian Pharmacopoeia (IP) • Supported by COPP and Written Confirmation (WC) Applications in Medical Fields: • Iron Deficiency Anemia Treatment • Chronic Kidney Disease • Rapid Iron Replenishment • Postpartum Anemia • Chronic Heart Failure • Inflammatory Bowel Disease